Opus Genetics, Inc. Asset Resilience Ratio
Opus Genetics, Inc. asset resilience ratio. Opus Genetics, Inc. (IRD) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRD defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Opus Genetics, Inc. (2020–2025)
Asset resilience ratio of Opus Genetics, Inc. from 2020 to 2025. This chart shows how Opus Genetics, Inc.'s Asset Resilience Ratio has changed over time. Read how much debt does Opus Genetics, Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Opus Genetics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Opus Genetics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Opus Genetics, Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Opus Genetics, Inc. Industry Peers by Asset Resilience Ratio
Compare Opus Genetics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Opus Genetics, Inc. Asset Resilience Ratio by Year (2020–2025)
Opus Genetics, Inc. asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Opus Genetics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | $0.00 | $50.24 Million | -- |
| 2024-12-31 | 0.01% | $2.00K | $36.86 Million | -0.02pp |
| 2023-12-31 | 0.03% | $15.00K | $53.95 Million | -0.07pp |
| 2022-12-31 | 0.10% | $49.00K | $48.99 Million | -0.74pp |
| 2021-12-31 | 0.84% | $219.00K | $26.08 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $17.68 Million | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more